Hamilton TCD 传感器在 Pichia pastoris 发酵过程中的验证应用说明
Application Note - Validation of Hamilton TCD Sensor During Pichia pastoris Fermentation
应用说明聚焦 Hamilton TCD 传感器在 Pichia pastoris 发酵过程中的验证。原文未给出验证方案、版本号、批次或适用范围等具体细节。
News|Articles|November 19, 2026
Related to this article
November 19th, 2026
Mazen Noureddin, MD, MHSc, of Houston Methodist Hospital discusses phase 2 data for GSK's once-monthly FGF21 analog efimosfermin presented at The Liver Meeting 2026 and what the findings mean for ongoing phase 3 trials in MASH and compensated cirrhosis.
November 19th, 2026
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
November 19th, 2026
In the first part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains which early patient responses led to the dostarlimab study behind Jemperli's rectal cancer approval, and why mismatch repair-deficient tumors are so visible to the immune system.
November 19th, 2026
Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.
November 19th, 2026
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
November 19th, 2026
DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.
November 19th, 2026
A second cereblon E3 ligase modulator from the Evotec and Bristol Myers Squibb degrader partnership is set to begin phase 1 testing in 2027.
November 18th, 2026
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
来源:BioPharm International · biopharminternational.com






